Results 221 to 230 of about 147,755 (251)
Some of the next articles are maybe not open access.
Anti-obesity drugs and neural circuits of feeding
Trends in Pharmacological Sciences, 2008Most of the drugs that have entered the market for treating obesity were originally developed to treat psychiatric diseases. During the past decade, understanding of the neural circuits that underlie food intake has increased considerably. Different aspects of ingestive behavior such as meal termination, meal initiation and overconsumption of highly ...
Roger A H, Adan +2 more
openaire +2 more sources
Capsaicin as an Anti-Obesity Drug
2014Laboratory studies support a role of capsaicin as an anti-obesity agent. Intestinal mucosal afferent nerves appear to play a role in controlling adipose tissue distribution between visceral and subcutaneous sites. Activation of the transient receptor potential vanilloid-1 channels by capsaicin prevents adipogenesis. A neurogenic mechanism modulates the
openaire +2 more sources
The discovery and status of sibutramine as an anti-obesity drug
European Journal of Pharmacology, 2002Sibutramine is a serotonin-norepinephrine reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet. Though sibutramine was originally evaluated for possible use as an antidepressant, its research development was eventually redirected to evaluate it as an anorexiant.
Carla A, Luque, Jose A, Rey
openaire +2 more sources
2000
The article contains sections titled: 1. Introduction 2. Animal and Human Test Procedures 3. Mechanism of Action 4. Clinical Side Effects 5. Phenethylamine Derivatives 5.1. β-Phenylisopropylamines 5.2. β-Phenyl-tert-butylamines 5.3. β-Phenyl-β-oxyisopropylamines 5.4. 1-Methyl-2-phenylmorpholines 6. Other Compounds 7. Economic
openaire +1 more source
The article contains sections titled: 1. Introduction 2. Animal and Human Test Procedures 3. Mechanism of Action 4. Clinical Side Effects 5. Phenethylamine Derivatives 5.1. β-Phenylisopropylamines 5.2. β-Phenyl-tert-butylamines 5.3. β-Phenyl-β-oxyisopropylamines 5.4. 1-Methyl-2-phenylmorpholines 6. Other Compounds 7. Economic
openaire +1 more source
Clinical Evaluation of Anti-Obesity Drugs
Current Drug Targets, 2004Obesity is a major health problem and as a result, it is reasonable to consider pharmacological approaches alongside approaches involving diet, physical activity and lifestyle change. The currently available drugs, sibutramine and orlistat, result in modest, clinically worthwhile weight loss, with demonstrable improvements in co-morbidity, but do not ...
openaire +2 more sources
PYY3‐36 as an anti‐obesity drug target
Obesity Reviews, 2005SummaryThe neuropeptide Y (NPY)/peptide YY (PYY) system has been implicated in the physiology of obesity for several decades. More recently, Batterhamet al.2002 ignited enormous interest in PYY3‐36, an endogenous Y2‐receptor agonist, as a promising anti‐obesity compound.
M M, Boggiano +36 more
openaire +2 more sources
A Risk-Benefit Assessment of Anti-Obesity Drugs
Drug Safety, 1999This review evaluates the benefits and potential health risks of the currently used drugs that are approved for the pharmacological treatment of obesity. Analysis of several long term clinical trials indicates that all of these drugs are efficient in reducing excess bodyweight, and that the majority of them allow the maintenance of the reduced ...
openaire +2 more sources
Why are anti-obesity drugs stigmatized?
Expert Opinion on Drug Safety, 2014Obesity is a common and morbid disease, but its treatment remains far from ideal. Many doctors, regulatory agencies, media outlets and patients consider lifestyle modification as the only possible intervention. Pharmacological agents, although with limitations, are useful weapons but are highly stigmatized. Some reasons for this stigma are discussed in
Bruno, Halpern, Alfredo, Halpern
openaire +2 more sources
Acta medica Austriaca, 2005
Obesity is a chronic disease with a worldwide increasing incidence. The mainstay of therapy consists in modification of behaviour related to obesity such as overeating and physical inactivity. When these life-style modifying attempts fail, the use of anti-obesity drugs is warranted.
Barbara, Tripp, Bernhard, Ludvik
openaire +1 more source
Obesity is a chronic disease with a worldwide increasing incidence. The mainstay of therapy consists in modification of behaviour related to obesity such as overeating and physical inactivity. When these life-style modifying attempts fail, the use of anti-obesity drugs is warranted.
Barbara, Tripp, Bernhard, Ludvik
openaire +1 more source